# A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

> **NCT05919030** · PHASE3 · RECRUITING · sponsor: **Renmin Hospital of Wuhan University** · enrollment: 155 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Intensity-modulated radiotherapy (IMRT)
- **DRUG:** Tislelizumab
- **DRUG:** Cisplatin
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05919030
- **Lead sponsor:** Renmin Hospital of Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919030, "A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05919030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*